FORMYCON AG news, videos and press releases - Page 4
For more news please use our advanced search feature.
FORMYCON AG - More news...
FORMYCON AG - More news...
- DGAP-News: Formycon Reports its Nine-month Figures for 2020
- DGAP-News: Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R)* (Ustekinumab)
- DGAP-Adhoc: Formycon informs about the modified BLA-Submission Strategy for its Lucentis(R)* Biosimilar-Candidate FYB201
- DGAP-News: Formycon Announces Virtual Annual General Meeting for December 10, 2020
- DGAP-News: Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation
- DGAP-News: Strategic Investor Active Ownership Group Subscribes for Cash Capital Increase of EUR 25.75 million
- DGAP-Adhoc: Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor
- DGAP-News: Formycon Announces Half-Year Results for 2020
- DGAP-News: Formycon and Bioeq Enroll First Patient in Phase III Study with Aflibercept Biosimilar (FYB203)
- DGAP-News: Formycon Reports Financial Results for the First Quarter of 2020
- DGAP-News: Formycon Publishes Annual Financial Statements for the 2019 Financial Year
- DGAP-News: Formycon Announces Update on Biosimilar Programs
- DGAP-News: Formycon is postponing the general assembly into the fourth quarter of 2020 to maintain the possibility of an event in person
- DGAP-News: Formycon Starts Antibody-Based Drug Development for COVID-19
- DGAP-News: Formycon informs about the current Status of the BLA Review Process of the Lucentis(R)* Biosimilar Candidate FYB201
- DGAP-News: Formycon AG: Formycon Reports its Nine-Month Figures for 2019
- DGAP-News: Formycon AG: Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202
- DGAP-News: Formycon AG: Formycon Publishes Half-Year Results for 2019
- DGAP-News: Formycon AG: Formycon reports on Annual General Meeting 2019
- DGAP-News: Formycon AG: Formycon Publishes Figures for the First Quarter of 2019
- DGAP-News: Formycon AG: Formycon Reports Successful 2018 Financial Year
- DGAP-News: Formycon AG: Formycon Announces News on Development Portfolio
- DGAP-News: Formycon AG: Strategic Investor M&H Equity AG Subscribes Cash Capital Increase of Euro 17.3 Million
- DGAP-News: Formycon AG: Formycon Releases Updates on Development Programs and Milestones
- DGAP-News: Formycon Reports Nine-Month Figures for 2018
- DGAP-News: Formycon AG: Formycon Reports Financial and Operating Results for the First Half Year of 2018
- DGAP-News: Formycon AG: Formycon Appoints Development and Production Expert Thomas Siklosi to the Advisory Board
- DGAP-News: Formycon AG: Formycon with Significant Growth in Turnover and Earnings in the First Quarter of 2018
- DGAP-News: Formycon AG: Formycon With Successful 2017 Financial Year
- DGAP-News: Formycon AG: Formycon and Bioeq Achieve Important Milestone: Biosimilar Ranibizumab Candidate FYB201 Shows Efficacy Comparable to the Reference Product in Phase III Study